10 maj: Indre værdi af SmallCap Danmark A/S er opgjort til 10,6 kr. pr. a..
10 maj: Danske Bank udnævner ny administrerende direktør
10-05-2019 08:10:22

Ambu A/S: Ambu appoints new CEO

Ambu’s board of directors has appointed Juan-José Gonzalez as the new CEO, effective May 15, 2019, to replace Lars Marcher who resigns from his position.

Jens Bager, Chairman of the Ambu Board of Directors, comments, “During Lars Marchers' leadership, Ambu has developed a strong and broad platform of medtech products, which have formed the basis for impressive growth. I and the rest of the board would like to thank Lars very much for his contribution to this remarkable decade in Ambu’s history. At the same time, I am pleased to have secured Juan-José Gonzalez, whom I am confident will be an excellent successor and the right choice to lead Ambu into its next growth phase.

Juan-José Gonzalez is an engineer and MBA graduate and has held a number of senior positions in the US healthcare group Johnson & Johnson for the past 12 years. Most recently, he has been President for the activities of the subsidiary DePuy Synthes in the US, with a turnover of DKK 33bn and more than 5,000 employees. DePuy Synthes is one of the world's leading manufacturers of orthopedic and neurosurgical products. Prior to joining Johnson & Johnson in 2007, Juan-José Gonzalez was a commercial director of the pharmaceutical company Pfizer, responsible for Europe, Africa and the Middle East, and for five years employed by the global consulting firm McKinsey & Company. Juan-José Gonzalez is 46 years old, an American citizen and relocates from the United States to Denmark with his wife and their two children.

"Ambu is facing a major international breakthrough with a number of high-tech products in the business area of Visualization with a broad program of single-use endoscopes in the USA and the rest of the world. With Juan-José Gonzalez as CEO, we ensure that Ambu also has the necessary global experience to execute the announced strategy and ensure the succesful commercialization of our product launches,” says Jens Bager.

Juan-José Gonzalez looks forward to joining Ambu as the new CEO. “The strength of Ambu is the company’s ability to deliver on differentiated innovation. Its pioneering of single-use endoscopy is a great example of Ambu’s focus on innovation. I am deeply committed to the plan to continue Ambu’s legacy of bringing innovative products to patients around the world. With Ambu’s recent launches, strong pipeline and committed people, I am very confident about our future." says Juan-José Gonzalez.

Financial expectations

The replacement of the CEO does not change the announced financial expectations for 2018/19 – except for the one-off costs listed below – or the financial targets for 2020 as outlined in the Big Five strategy. Planned product launches up to the end of the financial year 2019/20 and Ambu´s program for the upcomming DDW congress in San Diego on 18-21 May 2019 is thus unaffected by this.

In relation to Lars Marcher's resignation, there will be one-off costs of approx. DKK 38m, which for accounting purposes will be recognized in the income statement as Special items. The costs relates, among other things, to salary during the period of notice and the costs of the remaining value of already granted share options calculated according to the Black Scholes formula. These Black Scholes costs amounts to DKK 16m which so far has been distributed over the allocation period of the share options, but will now be fully charged to the income statement in the 3rd quarter of the financial year 2018/19 as a direct consequence of Lars Marcher's resignation.Before special items as referred above the financial expectations for the financial year 2018/19 are unchanged compared to the guidance provided in the interim report for our 2nd quarter on May 1, 2019, and can hereafter be summarized as:

  • Organic growth of approx. 15-16%.
  • EBIT margin before special items of approx. 22-24%.
  • Free cash flow of approx. DKK 400-475m.

Contact

For further information please contact:

Jens Bager, Chairman of the Board, tel. +45 2299 0304

Michael Højgaard, CFO, tel. +45 4030 4349

Press Inquiries: Morten Huse Eikrem-Jeppesen, PressConnect, tel. +45 5385 0770

Attachment

logo.png

Relateret indhold
25 jun - 
Tirsdagens aktier: Mærsk og bankaktierne minimerede plu..
25 jun - 
Aktier/middag: Danske Bank-nyt presser banker i småsurt..
25 jun - 
Aktier/åbning: Ambu fortsætter nedturen i generelt pres..
Relateret debat
25 jun - 
Juan Jose Gonzalez Snuppede lige 55.000 aktier i dag 💪
25 jun - 
Det gør danske for de lukker over 100 idag. den er svin..
25 jun - 
Nu har Nordea sænket kursmålet - og det er jo nok for e..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 jun
AMBU-B
Jeg synes at kritikken har være unødvendig skarp mod bestyrelsen og Jens Bager. For mig at se, gør s..
12
19 jun
AMBU-B
Bestyrelsen inkl Bager må da også have deres del af æren for at det igennem lang tid har gået så god..
11
20 jun
AMBU-B
Optrend...? Du må altså kunne se noget som vi andre ikke kan....  
7
19 jun
AMBU-B
Egerton Capital (UK) LLP has reduced his short position to 0 shares issued by Ambu A/S Ambu A/S   ME..
7
20 jun
AMBU-B
Juan Jose Gonzalez fokus skal da være 100% på selskabets drift og fremtid, så må aktiekursen mere el..
6
20 jun
AMBU-B
Så kom den i optrend, effektivt!   /tow
6
19 jun
AMBU-B
Overhovedet ikke. Ambu har et kæmpe vækst potentiale. Omsætning forventes at komme op, hvorfor marke..
6
25 jun
AMBU-B
Eller først til 80 ;)    
5
19 jun
AMBU-B
Jeg hæfter mig ved Børsen d.d.: “Jeg ved ikke hvor ofte, man har set en virksomhed med en OMSÆTNING ..
5
19 jun
AMBU-B
Det er helt tydeligt, at Lars Marcher gjorde alt for at tale kursen op. Så kunne han sælge ud af sin..
5

Vestas indgår forlig med GE i patentsag: Betaler fortroligt beløb

25-06-2019 16:36:29
Vestas har indgået forlig med den amerikanske rival Generel Electric i forbindelse med flere patentsager. Det betyder, at sagerne nu droppes, oplyser de to selskaber i en meddelelse.Vestas betaler i forbindelse med forliget en fortrolig sum penge til GE. Derudover giver forliget en krydslicens til paterne, der omhandler teknologi, der bruges til at sikre stabiliteten i vindmøllerne under forstyrre..

Amerikanske medicinalvirksomheder slår sig sammen i millardhandel

Relaterede nyheder
25-06-2019 13:05:35
Den amerikanske medicinalvirksomhed Abbvie overtager sin kollega Allergan i en handel til en værdi af 63 mia. dollar.Det bekræfter de to selskaber, efter at Wall Street Journal tidligere tirsdag kunne citere kilder for, at opkøbet var på vej.Ifølge aftalen betaler Abbvie 188,24 dollar per aktie i Allergan, svarende til en præmie på 45 pct. sammenlignet med lukkekursen på Allergan mandag.Aktien i A..

Mærsk lancerer nyt onlineprodukt: Vil bryde med overbookinger

25-06-2019 10:36:22
(Korr: ændring i andet afsnit. Ordet "betales" er ændret til "aftales".)A.P. Møller-Mærsk lancerer et nyt onlineprodukt, der skal være med til at gøre transporten af containere mere simpel for kunderne, og som samtidig kan være med til at undgå overbookinger.Produktet går under navnet Maersk Spot, og det sikrer kunderne en garanti for, at fragten bliver lastet, skriver Mærsk i en pressemeddelelse ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Britisk investeringsfirma reducerer shortposition i to danske aktier
2
Danske Bank/Nordea: Sænker kursmål med 10 kr.
3
Detektivfirma: Danske Bank fyrede os af frygt for hvidvasksag
4
Aktier/tendens: Inspirationen hælder mest til den negative side
5
Ørsted lægger to enheder sammen: Koncerndirektør forlader selskabet

Relaterede aktiekurser

Ambu A/S 91.62 -0,9% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. juni 2019 00:49:23
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB5 - 2019-06-26 00:49:23 - 2019-06-26 00:49:23 - 1 - Website: OKAY